Reduction in Acute Limb Ischemia With Rivaroxaban V
Disease After Lower Extremity Revascularization: Insig

Circulation

144, 1831-1841

DOI: 10.1161/circulationaha.121.055146

Citation Report

#	Article	IF	Citations
1	Navigating the Passage for Better Understanding and Prognosis for Acute Limb Ischemia After Lower-Extremity Revascularization. Circulation, 2021, 144, 1842-1844.	24.6	2
2	Medial Arterial Calcification: A Significant and Independent Contributor of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 253-260.	7.9	70
3	Rivaroxaban bei paVK-bezogene akute Extremitätenischämie. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2022, 9, 38-38.	0.0	0
4	Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	5.0	15
5	Lnc'ing Metabolic Regulation of Epigenetic Modifications to Atherosclerotic Calcification. Circulation Research, 2022, 130, 1583-1585.	15.7	0
6	Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. Canadian Journal of Cardiology, 2022, 38, 560-587.	3.8	134
7	High Rates of Recurrent Revascularization in Acute Limb Ischemia – A National Surgical Quality Improvement Program Study. Annals of Vascular Surgery, 2022, 87, 334-342.	1.8	5
8	What Is the Best Treatment for Acute Limb Ischemia?. Advances in Surgery, 2022, 56, 287-304.	2.1	9
9	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100513.	2.3	25
10	A Multicenter, Randomized, Open-Labelled, Non-Inferiority Trial of Sustained-Release Sarpogrelate Versus Clopidogrel After Femoropopliteal Artery Intervention. Scientific Reports, 2023, 13, 1-10.	5.2	5
11	Evidenzbasierte Gefäßchirurgie. Evidenzbasierte Chirurgie, 2022, .	0.0	2
12	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of Cardiovascular Development and Disease, 2023, 10, 164.	2.9	21
13	Acute Ischemia of the Upper and Lower Limbs: Tailoring the Treatment to the Underlying Etiology. Seminars in Vascular Surgery, 2023, 36, 211-223.	2.8	26
14	Thromboembolische Erkrankungen Aus Angiologischer Sicht. Deutsche Medizinische Wochenschrift, 2023, 148, 890-898.	0.3	1
15	Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients With Peripheral and Chronic Coronary Artery Disease: An Updated Review. Journal of Clinical Medicine, 2023, 12, 5284.	3.8	8
16	Phenotype-Directed Clinically Driven Low-Dose Direct Oral Anticoagulant for Atrial Fibrillation. Future Cardiology, 2023, 19, 405-417.	1.2	0
17	Sex and Racial Disparities in Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 2099-2114.	7.9	26
18	Akute Beinischämie: ein Update zu Diagnose und Management. Aktuelle Kardiologie, 2023, 12, 378-383.	0.0	0

#	Article	IF	Citations
19	Efficiency and Safety of Dual Pathway Inhibition for the Prevention of Femoropopliteal Artery Restenosis in Repeated Endovascular Interventions. Journal of Vascular Surgery, 2024, 79, 623-631.e2.	3.4	1
20	Efficacy and Safety of Combination Therapy With Low-Dose Rivaroxaban in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2024, 13, 2033.	3.8	1
21	Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association, 2024, 13, e032782.	5.8	11
22	Contemporary Therapy of Femoropopliteal In-Stent Restenosis / Occlusion, 36-Month Follow Up Study. Vascular and Endovascular Surgery, 2024, 58, 693-700.	0.9	4
23	Rivaroxaban and Aspirin in Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis: A Retrospective Cohort Study. Annals of Vascular Surgery, 2024, 108, 338-345.	1.8	4
24	Editor's Choice – Major Adverse Limb Events in Patients Undergoing Revascularisation for Lower Limb Peripheral Arterial Disease: A Nationwide Observational Study☆. European Journal of Vascular and Endovascular Surgery, 2024, 68, 737-745.	3.2	30
25	Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. Journal of the American College of Cardiology, 2024, 84, 936-952.	12.0	24
26	2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases: Developed by the Task Force on the Management of Peripheral Arterial and Aortic Diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). European Heart Journal, 2024, 45, 3538-3700.	14.7	1,197
27	Dynamic Perioperative Platelet Activity and Cardiovascular Events in Peripheral Artery Disease. Journal of Vascular Surgery, 2025, 81, 432-440.e3.	3.4	2
28	Incidence of Compartment Syndrome Following Peri-Pandemic Intervention for Non-Traumatic Acute Limb Ischemia. Vascular and Endovascular Surgery, 2025, 59, 360-366.	0.9	2
29	Brazilian Society of Angiology and Vascular Surgery Guidelines on Peripheral Artery Disease. Jornal Vascular Brasileiro, 2024, 23, e20230059.	1.0	11
30	No Title. , 0, .		0
31	Risk Factors of Incident Acute Limb Ischemia After Contemporary Femoropopliteal Endovascular Revascularization From a Multicenter Registry: A Retrospective Observational Study. JRSM Cardiovascular Disease, 2025, 14, 20480040251325412.	0.9	1
32	Society for Vascular Surgery Clinical Practice Guideline on the Management of Intermittent Claudication: Focused Update. Journal of Vascular Surgery, 2025, 82, 303-326.e11.	3.4	28
33	Aspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial. International Cardiovascular Research Journal, 2025, 19, e154736.	0.4	1
34	Revascularization for Claudication in the Setting of Multi-Level And/Or Bilateral Disease: How Many Levels to Treat and How. , 2025, .		0
35	Management of Bilateral Acute Lower Limb Ischemia in Patients With Prolonged International Normalized Ratio and Thrombocytopenia. International Journal of Angiology, 2025, .	1.1	0
36	Impact of Peripheral Artery Disease (PAD) on Risk of Major Adverse Cardiovascular Events (MACE) in Patients With Type 2 Diabetes. American Journal of Preventive Cardiology, 2026, 25, 101397.	5.0	1

#	Article	IF	Citations
37	Effect of Rivaroxaban on DNA Damage in an Ischemia-Reperfusion Model: Evaluation of 8-OHdG Levels. Experimental and Therapeutic Medicine, 2026, 31, 1-7.	2.4	1
38	Asymptomatic Peripheral Arterial Disease and Intermittent Claudication: An Overview. , 2026, .		0
39	Timing of Restenosis and Reocclusion Following Endovascular Therapy for Femoropopliteal Lesions. Cureus, 2026, 18, e107342.	1.3	0
40	Peripheral Artery Disease Prognosis and Outcomes: Scoping Review With ❁SAIMSARA. , 2026, .		0
41	Peripheral Artery Disease and Amputation: Scoping Review With ❁SAIMSARA. , 2026, .		0
42	Rivaroxaban for the Prevention of Atherothrombotic Events in Advanced CKD: Are We Off TRACK?. CKJ: Clinical Kidney Journal, 2026, 19, sfag220.	4.8	1
43	Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial. Circulation, 2026, 154, 966-975.	24.6	2
44	PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction. Medicina (Lithuania), 2026, 62, 1905.	3.3	0